Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert Villeirs

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 13, 2012
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched studyKatrien Vandecasteele, Louke Delrue, Bieke Lambert, et al.
Urologic Oncology|February 4, 2017
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapiesTom Claeys, Nicolaas Lumen, Candy Kumps, et al.
European Urology|February 7, 2015
Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the LiteratureJurgen J Fütterer, Alberto Briganti, Pieter De Visschere, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 17, 2009
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementationKatrien Vandecasteele, Wilfried De Neve, Werner De Gersem, et al.
The Prostate|November 1, 2014
Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancerTijl Vermassen, Charles Van Praet, Nicolaas Lumen, et al.
Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 3, 2018
ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancerCarl Salembier, Geert Villeirs, Berardino De Bari, et al.
Urologic Oncology|January 17, 2018
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trialSarah Buelens, Filip Poelaert, Bert Dhondt, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 TrialValérie Fonteyne, Camille Sarrazyn, Martijn Swimberghe, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 11, 2013
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcomeValérie Fonteyne, Nicolaas Lumen, Piet Ost, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 13, 2012
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched studyKatrien Vandecasteele, Louke Delrue, Bieke Lambert, et al.
Urologic Oncology|February 4, 2017
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapiesTom Claeys, Nicolaas Lumen, Candy Kumps, et al.
European Urology|February 7, 2015
Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the LiteratureJurgen J Fütterer, Alberto Briganti, Pieter De Visschere, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 17, 2009
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementationKatrien Vandecasteele, Wilfried De Neve, Werner De Gersem, et al.
The Prostate|November 1, 2014
Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancerTijl Vermassen, Charles Van Praet, Nicolaas Lumen, et al.
Nature Reviews. Urology|July 19, 2019
Multiparametric MRI for prostate cancer diagnosis: current status and future directionsArmando Stabile, Francesco Giganti, Andrew B Rosenkrantz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 3, 2018
ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancerCarl Salembier, Geert Villeirs, Berardino De Bari, et al.
Urologic Oncology|January 17, 2018
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trialSarah Buelens, Filip Poelaert, Bert Dhondt, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 TrialValérie Fonteyne, Camille Sarrazyn, Martijn Swimberghe, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 11, 2013
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcomeValérie Fonteyne, Nicolaas Lumen, Piet Ost, et al.
Pageof 10